Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Source: onclive.com
Stay updated with breaking news from Ashwin Kishtagari. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Ashwin Kishtagari, MD, discusses how momelotinib addresses unmet needs in the management of anemic myelofibrosis following disease progression on ruxolitinib.